Vibativ approval hold lifted in Europe
This article was originally published in Scrip
Executive Summary
The European suspension of the marketing authorization for Vibativ (telavancin) has been lifted. This clears the way for Clinigen of the UK, which licensed European rights to the antibiotic from Theravance last March, to begin its commercial launch, which is now anticipated during the second quarter.